Clinical trials
Pharmacokinetics and Pharmacodynamics clinical trials
Below are recruiting pharmacokinetics and pharmacodynamics clinical trials, each written for real people, not researchers. We’re tracking 137 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07182552Enrolling by invitationPhase 1
Testing a new drug NTB003 in healthy volunteers
This early-phase trial tests the safety of a new drug called NTB003 in healthy people. It looks at how the drug moves through the body and affects it, which is a first step toward possibly treating certain conditions.
BeijingAges 25–45 - NCT07166081RecruitingPhase 1
Study of BGM0504 tablets in overweight or obese adults
This study tests an investigational tablet called BGM0504 for weight management in adults with overweight or obesity but without diabetes. It looks at how the drug works in your body and how safe it is over time.
Baltimore, MarylandAges 18–65 - NCT06752746RecruitingPhase 1
Testing 9MW3011 for polycythemia vera in resistant patients
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
Zhengzhou, HenanAges 18 years+ - NCT07098091Enrolling by invitationPhase 1
Testing the safety of YD0293 in healthy adults
This phase 1 study tests a new medicine called YD0293 in healthy volunteers to see if it is safe and how the body handles it. It helps find the right dose for future studies.
Suzhou, JiangsuAges 18–45 - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT06987539RecruitingPhase 2
Inebilizumab for children with generalized myasthenia gravis
This study tests a new drug called inebilizumab for children with generalized myasthenia gravis (gMG), a condition causing muscle weakness. The drug aims to reduce the immune system's attack on nerves, which may improve symptoms. The study will check how safe and effective it is for young patients.
Philadelphia, PennsylvaniaAges 2–17 - NCT05205109RecruitingPhase 1
Testing a new melanoma drug alone and with pembrolizumab
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
Sydney, New South WalesAges 18 years+ - NCT06609005RecruitingPhase 1/Phase 2
Study of INV-9956 for advanced prostate cancer
This trial tests a new drug called INV-9956 in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It aims to see if the drug is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT05371886Recruiting
Testing how morphine (with or without midazolam) behaves in NICU babies
This study measures how morphine works in very young babies, and whether adding midazolam changes how the medicines behave and affect the body. It may help doctors better choose and dose pain/sedation medicines for babies in intensive care.
BrestAges 5 months–10 months - NCT05987449RecruitingPhase 1/Phase 2
Study of NXT007 for people with hemophilia A
This study tests a new medicine called NXT007 for people with moderate or severe hemophilia A. The goal is to see if it is safe, well-tolerated, and can help prevent or reduce bleeding episodes, possibly reducing the need for standard treatments. You may be able to join if you have hemophilia A with or without inhibitors and meet other health requirements.
Sacramento, CaliforniaAges 2–59 - NCT05222529RecruitingPhase 2
Study medicine dosing in children with asthma using inhaler tests
This Phase 2 study checks how glycopyrronium bromide works in children with asthma, including its safety and how well inhaler dosing is tolerated. It also uses breathing tests and inhaler technique checks to confirm your child meets key asthma and lung function requirements.
RousseAges 6–11 - NCT04833894RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
Chicago, IllinoisAges 2–18 - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Phoenix, ArizonaAges birth–20 years - NCT05318534RecruitingPhase 1
Testing a new medicine for Cold Agglutinin Disease
This Phase 1 study checks whether an investigational medicine is safe and tolerable, and how the body processes it. For people with Cold Agglutinin Disease, it also looks at early blood markers of whether the disease responds.
LeedsAges 18 years+ - NCT07867288RecruitingPhase 1
Study of an investigational drug for non-obstructive hypertrophic cardiomyopathy
This trial tests an investigational drug given as an injection under the skin for people with a type of hypertrophic cardiomyopathy that does not block blood flow out of the heart. The goal is to see if the drug is safe and may help improve symptoms.
Kansas City, MissouriAges 18–70 - NCT06767566RecruitingPhase 1
Ketamine for depression and pain after cesarean delivery
This study tests whether ketamine, a medicine given during cesarean delivery, can help prevent or reduce postpartum depression and pain. It aims to find the best dose for new mothers.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07842640RecruitingPhase 1
Injectable treatment for overweight and obesity
This study tests an injectable medication called ASC35 to see if it is safe and tolerable for people who are overweight or obese. It may help with weight management, though it is an early-stage trial focused on safety first.
Baltimore, MarylandAges 18–65 - NCT07798505RecruitingPhase 1
Safety study of a new drug HMB-003 in healthy adults
This study is testing a new investigational drug called HMB-003 to see how safe it is and how it behaves in the body. It is for healthy volunteers and will help determine whether the drug can be studied further in people with certain conditions.
San Antonio, TexasAges 18–50 - NCT07786779RecruitingPhase 1
Safety study of an injectable drug in healthy adults
This study tests a new injectable medication to see if it is safe and how the body processes it. It is looking for healthy adults to participate and will monitor for side effects and study how the drug works.
Beijing, Beijing MunicipalityAges 18–55 - NCT07785934RecruitingPhase 1
Testing a new weight management injection for drug interactions
This study tests a new injectable medication for weight management in people with overweight or obesity. It investigates how the drug interacts with other medications and checks its safety. Participation requires a 6-month commitment with regular study visits.
Hefei, AnhuiAges 18–45 - NCT07758595RecruitingPhase 1
Study of DNL921 for healthy people and people with Alzheimer's disease
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
ManchesterAges 18–75 - NCT07749651RecruitingPhase 1
Single-dose safety study of SHR-7012 in healthy adults
This study tests a single dose of a new drug called SHR-7012 in healthy volunteers to check if it is safe and how the body handles it. It is a first-in-human trial, so participants will be closely monitored.
Hangzhou, ZhejiangAges 18–55 - NCT07717905RecruitingPhase 1/Phase 2
Testing BBT001 for chronic hives
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Wuhu, AnhuiAges 18–75
Hear when a new Pharmacokinetics and Pharmacodynamics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pharmacokinetics and pharmacodynamics?
- Yes. Clin2 currently lists 137 recruiting pharmacokinetics and pharmacodynamics studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pharmacokinetics and pharmacodynamics trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pharmacokinetics and pharmacodynamics trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.